CNR1 and metabolic dysfunction-associated steatotic liver disease: Thus, it can be deduced that peripheral CB1R hyperactivation promotes obesity-associated fatty liver, suggesting that the CB1R blockade could serve as a therapeutic strategy for NAFLD.